Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy

Title:Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy

Volume: 24 Issue: 5

Author(s): Deasmond O. Acheampong*, Christian K. Adokoh*, Paulina Ampomah, Daniel S. Agyirifor, Isaac Dadzie, Francis A. Ackah and Ernest A. Asiamah

Affiliation:

• Department of Biomedical Sciences, School of Allied Health Sciences, University of Cape Coast, Cape Coast,Ghana

• Department of Forensic Sciences, School of Biological Sciences, University of Cape Coast, Cape Coast,Ghana

Keywords: Antibody, bispecific antibody (BsAb), immunotherapeutic agent, cancer therapy, diabody, antitumor.

Abstract: Antibodies have become the preferred therapeutic treatment option for cancers. Antibody therapy is associated with low toxic profile and specific in its activity, unlike chemotherapy and radiotherapy. Types of tumor are known to express multiple receptors that cross-talk to activate perpetual growth, proliferation and metastasis, and inhibit apoptosis in such tumors. Bispecific antibodies (BsAbs) are therefore the preferred agent for the treatment of such cancers due to its unique characteristics. This review discusses up to date therapeutic potentials of BsAbs.

Cite this article as:

Acheampong O. Deasmond*, Adokoh K. Christian*, Ampomah Paulina, Agyirifor S. Daniel, Dadzie Isaac, Ackah A. Francis and Asiamah A. Ernest, Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy, Protein & Peptide Letters 2017; 24 (5) . https://dx.doi.org/10.2174/0929866524666170120095128